From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Trade names Synarel
AHFS/ monograph
MedlinePlus a601082
  • X
  • (Prescription only)
Nasal spray
Pharmacokinetic data
Half-life 2.6 to 4 hours
Excretion renal
76932-56-4 YesY
PubChem CID 25077649
DrugBank DB00666 YesY
ChemSpider 10482014 YesY
UNII 1X0094V6JV YesY
Chemical data
Formula C66H83N17O13
1321.6344 g/mol
 N (what is this?)  (verify)

Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary gland, it decreases pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, or to control ovarian stimulation in IVF.

Nafarelin acetate is marketed by Searle (now part of Pfizer) under the brand name Synarel. It is delivered via a nasal spray.

Side effects[edit]

Side effects of nafarelin are related to the low estrogen state. Side effects include hot flashes, vaginal dryness, headaches, mood changes, and decreased interest in sex. Some patients may experience acne, muscle pain, reduced breast size, and irritation of the tissue inside the nose. These side effects are reversible and should resolve after stopping the medication.[1]